Free Trial
NASDAQ:MRNS

Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis

$1.38
+0.08 (+6.15%)
(As of 05/24/2024 08:50 PM ET)
Today's Range
$1.29
$1.40
50-Day Range
$1.20
$9.30
52-Week Range
$1.11
$11.26
Volume
1.15 million shs
Average Volume
1.45 million shs
Market Capitalization
$75.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.79

Marinus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
899.0% Upside
$13.79 Price Target
Short Interest
Bearish
9.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.55
Upright™ Environmental Score
News Sentiment
0.47mentions of Marinus Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.87) to ($0.90) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.10 out of 5 stars

Medical Sector

169th out of 922 stocks

Pharmaceutical Preparations Industry

63rd out of 422 stocks

MRNS stock logo

About Marinus Pharmaceuticals Stock (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

MRNS Stock Price History

MRNS Stock News Headlines

Oppenheimer Reaffirms Their Hold Rating on Marinus (MRNS)
Marinus Pharmaceuticals: Q1 Earnings Snapshot
Marinus Pharmaceuticals Inc (MRNS)
Why Are Stocks Up Today?
See More Headlines
Receive MRNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/05/2024
Today
5/27/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MRNS
Employees
165
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.79
High Stock Price Target
$28.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+899.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-141,400,000.00
Net Margins
-513.80%
Pretax Margin
-519.24%

Debt

Sales & Book Value

Annual Sales
$30.99 million
Book Value
($0.30) per share

Miscellaneous

Free Float
51,935,000
Market Cap
$75.80 million
Optionable
Optionable
Beta
1.14
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Scott N. Braunstein M.D. (Age 61)
    CEO, President & Chairman
    Comp: $1.01M
  • Dr. Alex Aimetti Ph.D.
    Chief Scientific Officer
  • Ms. Sonya Weigle
    Senior VP of Investor Relations, Human Resources & Corporate Affairs
  • Ms. Martha E. Manning Esq. (Age 69)
    J. D., Senior VP, General Counsel & Secretary
  • Molly Cameron
    Director of Corporate Communications & Investor Relations
  • Dr. Kimberly A. McCormick Pharm.D.
    Chief Regulatory & Quality Assurance Officer
  • Mr. Thomas J. Lyons
    Chief Business Officer
  • Mr. David Czekai
    Senior Vice President of Chemistry, Manufacturing & Controls
  • Dr. Mark Paternoster Ph.D.
    Senior Vice President of Development
  • Dr. Dayong Li Ph.D.
    Senior Vice President of Biometrics

MRNS Stock Analysis - Frequently Asked Questions

Should I buy or sell Marinus Pharmaceuticals stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MRNS shares.
View MRNS analyst ratings
or view top-rated stocks.

What is Marinus Pharmaceuticals' stock price target for 2024?

7 Wall Street analysts have issued twelve-month price targets for Marinus Pharmaceuticals' stock. Their MRNS share price targets range from $3.00 to $28.00. On average, they anticipate the company's share price to reach $13.79 in the next twelve months. This suggests a possible upside of 899.0% from the stock's current price.
View analysts price targets for MRNS
or view top-rated stocks among Wall Street analysts.

How have MRNS shares performed in 2024?

Marinus Pharmaceuticals' stock was trading at $10.87 at the beginning of the year. Since then, MRNS shares have decreased by 87.3% and is now trading at $1.38.
View the best growth stocks for 2024 here
.

When is Marinus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our MRNS earnings forecast
.

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) issued its earnings results on Tuesday, March, 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.64) by $0.10. The biopharmaceutical company had revenue of $7.19 million for the quarter, compared to the consensus estimate of $7.78 million. Marinus Pharmaceuticals had a negative net margin of 513.80% and a negative trailing twelve-month return on equity of 518.13%. During the same quarter in the previous year, the firm posted ($0.76) EPS.

What ETFs hold Marinus Pharmaceuticals' stock?

ETFs with the largest weight of Marinus Pharmaceuticals (NASDAQ:MRNS) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

When did Marinus Pharmaceuticals' stock split?

Marinus Pharmaceuticals's stock reverse split before market open on Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What other stocks do shareholders of Marinus Pharmaceuticals own?
Who are Marinus Pharmaceuticals' major shareholders?

Marinus Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Avoro Capital Advisors LLC (7.54%), Vanguard Group Inc. (5.11%), Bain Capital Life Sciences Investors LLC (2.54%), Ikarian Capital LLC (0.00%), Hussman Strategic Advisors Inc. (0.13%) and Jacobs Levy Equity Management Inc. (0.08%). Insiders that own company stock include Christina Shafer, Martha E Manning, Scott Braunstein, Seth H Z Fischer and Steven Pfanstiel.
View institutional ownership trends
.

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRNS) was last updated on 5/27/2024 by MarketBeat.com Staff

From Our Partners